New Breast Cancer Patient Resource Is Available

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 5 No 11
Volume 5
Issue 11

WILMINGTON, Del-The Breast Cancer Patient Education Service, recently established by Zeneca Pharmaceuticals, allows breast cancer patients and their families to obtain patient education materials on tamoxifen (Nolvadex) with one phone call.

WILMINGTON, Del—The Breast Cancer Patient Education Service, recently established by Zeneca Pharmaceuticals, allows breast cancer patients and their families to obtain patient education materials on tamoxifen (Nolvadex) with one phone call.

The service provides the Progress for Life educational package, which includes written materials explaining breast cancer issues in easy-to-understand language and a video featuring experts on tamoxifen treatment, as well as useful toll-free numbers for other breast cancer information resources.

Patients can access the service by calling 1-800-34-LIFE-4 (1-800-345-4334), Monday through Friday, 8:15 AM until 4:30 PM Eastern Standard Time.

Recent Videos
Heather Zinkin, MD, states that reflexology improved pain from chemotherapy-induced neuropathy in patients undergoing radiotherapy for breast cancer.
Study findings reveal that patients with breast cancer reported overall improvement in their experience when receiving reflexology plus radiotherapy.
Patients undergoing radiotherapy for breast cancer were offered 15-minute nurse-led reflexology sessions to increase energy and reduce stress and pain.
Whole or accelerated partial breast ultra-hypofractionated radiation in older patients with early breast cancer may reduce recurrence with low toxicity.
Ultra-hypofractionated radiation in those 65 years or older with early breast cancer yielded no ipsilateral recurrence after a 10-month follow-up.
The unclear role of hypofractionated radiation in older patients with early breast cancer in prior trials incentivized research for this group.
Patients with HR-positive, HER2-positive breast cancer and high-risk features may derive benefit from ovarian function suppression plus endocrine therapy.
Paolo Tarantino, MD discusses updated breast cancer trial findings presented at ESMO 2024 supporting the use of agents such as T-DXd and ribociclib.
Paolo Tarantino, MD, discusses the potential utility of agents such as datopotamab deruxtecan and enfortumab vedotin in patients with breast cancer.
Paolo Tarantino, MD, highlights strategies related to screening and multidisciplinary collaboration for managing ILD in patients who receive T-DXd.
Related Content